Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection...
Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
About this item
Full title
Author / Creator
Publisher
Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Paliperidone palmitate 3-monthly (PP3M), an approved maintenance treatment for patients with schizophrenia, was the first long-acting antipsychotic injectable (LAI) to require only four administrations per year. Here, we aimed to review the available evidence about its use in the management of schizophrenia to date and highlight key study findings...
Alternative Titles
Full title
Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504906
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10504906
Other Identifiers
ISSN
1179-1365
E-ISSN
1179-1365
DOI
10.2147/DHPS.S339170
